Español

The term vitamin E describes a family of eight antioxidants: four tocopherols (α-, β-, γ-, and δ-) and four tocotrienols (α-, β-, γ-, and δ-). α-Tocopherol is the only form of vitamin E that is actively maintained in the human body; therefore, it is the form of vitamin E found in the largest quantities in blood and tissues (1). Because α-tocopherol is the form of vitamin E that appears to have the greatest nutritional significance, it will be the primary topic of the following discussion. It is also the only form that meets the latest Recommended Dietary Allowance (RDA) for vitamin E.

Function

α-Tocopherol

The main function of α-tocopherol in humans appears to be that of an antioxidantFree radicals are formed primarily in the body during normal metabolism and also upon exposure to environmental factors, such as cigarette smoke or pollutants. Fats, which are an integral part of all cell membranes, are vulnerable to destruction through oxidation by free radicals. The fat-soluble vitamin, α-tocopherol, is uniquely suited to intercept free radicals and thus prevent a chain reaction of lipid destruction. Aside from maintaining the integrity of cell membranes throughout the body, α-tocopherol also protects the fats in low-density lipoproteins (LDLs) from oxidation. Lipoproteins are particles composed of lipids and proteins that transport fats through the bloodstream. LDLs specifically transport cholesterol from the liver to the tissues of the body. Oxidized LDLs have been implicated in the development of cardiovascular disease (see Disease Prevention). When a molecule of α-tocopherol neutralizes a free radical, it is altered in such a way that its antioxidant capacity is lost. However, other antioxidants, such as vitamin C, are capable of regenerating the antioxidant capacity of α-tocopherol (2, 3).

Several other functions of α-tocopherol have been identified that are not likely related to its antioxidant capacity. For instance, α-tocopherol is known to inhibit the activity of protein kinase C, an important cell-signaling molecule. α-Tocopherol appears to also affect the expression and activities of molecules and enzymes in immune and inflammatory cells. Additionally, α-tocopherol has been shown to inhibit platelet aggregation and to enhance vasodilation (4, 5).

The isomeric form of α-tocopherol found in foods is RRR-α-tocopherol (also referred to as "natural" or d-α-tocopherol). Synthetic α-tocopherol, which is labeled all-rac- or dl-α-tocopherol, has only one-half the biological activity of RRR-α-tocopherol (see Supplements). Often vitamin E-fortified foods contain synthetic α-tocopherol, and the amounts are given as a percentage of the daily value of 30 IU. Throughout this article, amounts of α-tocopherol are expressed in both international units (IU) and milligrams (mg).

γ-Tocopherol

The function of γ-tocopherol in humans is presently unclear. Although the most common form of vitamin E in the American diet is γ-tocopherol (see Food sources), blood levels of γ-tocopherol are generally ten times lower than those of α-tocopherol. This phenomenon is apparently due to two mechanisms. (1) α-Tocopherol is preferentially retained in the body by the action of the α-tocopherol transfer protein (a-TTP) in the liver, which preferentially incorporates α-tocopherol into lipoproteins that are circulated in the blood (1) and ultimately delivers α-tocopherol to different tissues in the body (6). (2) Forms of vitamin E other than α-tocopherol are actively metabolized (6). Because γ-tocopherol is initially absorbed in the same manner as α-tocopherol, small amounts of γ-tocopherol are detectable in blood and tissue. Breakdown products of tocopherols, known as metabolites, can be detected in urine. More γ-tocopherol metabolites are excreted in urine than α-tocopherol metabolites, suggesting less γ-tocopherol is needed for use by the body (7). Limited research in the test tube and in animals indicates that γ-tocopherol or its metabolites may play a role in protecting the body from free radical-induced damage (8, 9), but these effects have not been convincingly demonstrated in humans. In one prospective study, increased levels of plasma γ-tocopherol were associated with a significantly reduced risk of developing prostate cancer. In this study, increased levels of plasma α-tocopherol and toenail selenium were protective against prostate cancer development only when γ-tocopherol levels were also high (10). These limited findings, in addition to the fact that α-tocopherol supplementation lowers γ-tocopherol levels in blood, have led some scientists to call for additional research on the effects of dietary and supplemental γ-tocopherol on health (11)

Deficiency

Vitamin E deficiency has been observed in individuals with severe malnutrition, genetic defects affecting the α-tocopherol transfer protein, and fat malabsorption syndromes.  For example, children with cystic fibrosis or cholestatic liver disease, who have an impaired capacity to absorb dietary fat and therefore fat-soluble vitamins, may develop symptomatic vitamin E deficiency. Severe vitamin E deficiency results mainly in neurological symptoms, including impaired balance and coordination (ataxia), injury to the sensory nerves (peripheral neuropathy), muscle weakness (myopathy), and damage to the retina of the eye (pigmented retinopathy). For this reason, people who develop peripheral neuropathy, ataxia, or retinitis pigmentosa should be screened for vitamin E deficiency (2). The developing nervous system appears to be especially vulnerable to vitamin E deficiency. For instance, children with severe vitamin E deficiency at birth rapidly develop neurological symptoms if not treated with vitamin E. In contrast, individuals who develop malabsorption of vitamin E in adulthood may not develop neurological symptoms for 10-20 years. It should be noted that symptomatic vitamin E deficiency in healthy individuals who consume diets low in vitamin E has never been reported (2, 12).

Although true vitamin E deficiency is rare, marginal intake of vitamin E is relatively common in the US Between 1988 and 1994, the National Health and Nutrition Examination Survey III (NHANES III) examined the dietary intake and blood levels of α-tocopherol in 16,295 adults (over the age of 18). Twenty-seven percent of white participants, 41% of African Americans, 28% of Mexican Americans, and 32% of the other participants were found to have blood levels of α-tocopherol less than 20 micromoles/liter. This cutoff value was chosen because the literature suggests an increased risk for cardiovascular disease below this level (13). More recent data from NHANES 2003-2006 indicate that the average dietary intake of α-tocopherol from food (including enriched and fortified sources) among Americans 2 years and older is 6.9 mg/day (14). This intake is well below the current recommendation of 15 mg/day (see RDA). In fact, at this level of dietary intake, more than 90% of Americans do not meet daily dietary recommendations for vitamin E (14).

The Recommended Dietary Allowance (RDA)

The RDA for vitamin E was previously 8 mg/day for women and 10 mg/day for men. The RDA was revised by the Food and Nutrition Board of the Institute of Medicine in 2000 (4; Table 1). This new recommendation was based largely on the results of studies done in the 1950s in men fed vitamin E deficient diets. In a test-tube analysis, hydrogen peroxide was added to blood samples and the breakdown of red blood cells, known as hemolysis, was used to indicate vitamin E deficiency. Because hemolysis has also been reported in children with severe vitamin E deficiency, this analysis was considered to be a clinically relevant test of vitamin E status. Importantly, this means that the latest RDA for vitamin E continues to be based on the prevention of deficiency symptoms rather than on health promotion and prevention of chronic disease.

Table 1. Recommended Dietary Allowance (RDA) for α-Tocopherol
Life Stage Age Males Females
mg/day IU/day mg/day IU/day
Infants (AI) 0-6 months
4
6
4
6
Infants (AI) 7-12 months
5
7.5
5
7.5
Children 1-3 years
6
9
6
9
Children 4-8 years
7
10.5
7.5
10.5 
Children     9-13 years
11
16.5
11
16.5 
Adolescents 14-18 years
15
22.5
15
22.5 
Adults 19 years and older
15
22.5
15
22.5
Pregnancy all ages
-
-
15
22.5
Breast-feeding all ages
-
-
19
28.5

Disease Prevention

Cardiovascular disease

Results of at least five large observational studies suggest that increased vitamin E consumption is associated with decreased risk of myocardial infarction (heart attack) or death from heart disease in both men and women. Each study was a prospective study that measured vitamin E consumption in presumably healthy people and followed them for a number of years to determine how many were diagnosed with or died as a result of heart disease. In two of the studies, individuals who consumed more than 7 mg/day of α-tocopherol in food were only approximately 35% as likely to die from heart disease as those who consumed less than 3-5 mg/day of α-tocopherol (15, 16). Two other large studies observed a significantly reduced risk of heart disease only in women and men who consumed at least 100 IU of supplemental RRR-α-tocopherol (67 mg of RRR-α-tocopherol) daily (17, 18). More recently, several studies have observed plasma or red blood cell levels of α-tocopherol to be inversely associated with the presence or severity of carotid atherosclerosis, detected using ultrasonography (19-22). A randomized, placebo-controlled, intervention trial in 39,876 women participating in the Women's Health Study found that supplementation with 600 IU of RRR-α-tocopherol (400 mg of RRR-α-tocopherol) every other day for ten years had no effect on the incidence of various cardiovascular events (myocardial infarction and stroke), but the vitamin E intervention decreased cardiovascular-related deaths by 24% (23). Analysis of data from the Women's Health Study also showed that women receiving the vitamin E intervention experienced a 21% reduction in risk of venous thromboembolism (24). However, a large RCT conducted in healthy middle-aged men (trial name: PHS II) observed that supplementation with 400 IU of synthetic α-tocopherol every other day for eight years had no significant effect on the risk of major cardiovascular events (25). The benefits of vitamin E supplementation in chronic disease prevention are discussed in a recent review (26). Intervention studies in patients with heart or renal disease have not shown vitamin E supplements to be effective in preventing heart attacks or death (see Disease Treatment).

Cataracts

Cataracts appear to be formed by protein oxidation in the lens of the eye; such oxidation may be prevented by antioxidants like α-tocopherol.  Several observational studies have examined the association between vitamin E consumption and the incidence and severity of cataracts. Results of these studies are mixed: some report increased vitamin E intake protects against cataract development, while others report no association (27). A placebo-controlled intervention trial in 4,629 men and women found that a daily antioxidant supplement containing 500 mg of vitamin C, 400 IU of synthetic vitamin E (dl-α-tocopherol acetate; equivalent to 180 mg of RRR-α-tocopherol), and 15 mg of β-carotene did not affect development and progression of age-related cataracts over a seven-year period (28). Similarly, antioxidant supplementation (500 mg of vitamin C, 400 IU [268 mg] of RRR-α-tocopherol, and 15 mg of β-carotene) did not affect progression of cataracts in a five-year intervention trial (29). A four-year randomized, placebo-controlled trial reported that supplements containing 500 IU/day of natural vitamin E (335 mg of RRR-α-tocopherol) did not reduce the incidence or progression of cataracts in older adults (30). Another intervention trial found that a daily supplement of 50 mg of synthetic α-tocopherol daily (equivalent to 25 mg of RRR-α-tocopherol) did not alter the incidence of cataract surgery in male smokers (31). Although results from some observational studies suggest that vitamin E may protect against cataract development, results from clinical trials do not support a preventative effect.

Immune Function

α-Tocopherol has been shown to enhance specific aspects of the immune response that appear to decline as people age. For example, elderly adults given 200 mg/day of synthetic α-tocopherol (equivalent to 100 mg of RRR-α-tocopherol or 150 IU of RRR-tocopherol) for several months displayed increased formation of antibodies in response to hepatitis B vaccine and tetanus vaccine (32). However, it is not known if such α-tocopherol associated enhancements in the immune response of older adults actually translate to increased resistance to infections like the flu (influenza virus) (33). A randomized, placebo-controlled trial in elderly nursing home residents reported that daily supplementation with 200 IU of synthetic α-tocopherol (equivalent to 90 mg of RRR-α-tocopherol) for one year significantly lowered the risk of contracting upper respiratory tract infections, especially the common cold, but had no effect on lower respiratory tract (lung) infections (34). More research is needed to determine whether supplemental vitamin E may protect the elderly against the common cold or other infections.

Cancer

Many types of cancer are thought to result from oxidative damage to DNA caused by free radicals. The ability of α-tocopherol to neutralize free radicals has made it the subject of a number of cancer prevention studies. However, several large prospective studies have failed to find significant associations between α-tocopherol intake and the incidence of lung or breast cancer (4). One study in a cohort of 77,126 men and women reported that use of vitamin E supplements over a 10-year period increased risk of lung cancer in current smokers (35). To date, most clinical trials have found that vitamin E supplementation has no effect on the risk of various cancers. A randomized, placebo-controlled trial (RCT) in 39,876 women participating in the Women's Health Study found that supplementation with 600 IU of RRR-α-tocopherol (400 mg of RRR-α-tocopherol) every other day for ten years had no effect on overall cancer incidence or cancer-related deaths (23). This vitamin E intervention also did not affect the incidence of tissue-specific cancers, including breast, lung, and colon cancers. Moreover, a recently published meta-analysis of 12 RCTs concluded that vitamin E supplementation was not associated with overall cancer incidence, cancer mortality, or total mortality (36).

The effect of vitamin E supplementation on prostate cancer risk has received particular attention in RCTs. A placebo-controlled intervention study that was designed to investigate the effect of α-tocopherol supplementation on lung cancer development (trial name: ATBC) noted a 34% reduction in the incidence of prostate cancer in smokers given daily supplements of 50 mg of synthetic α-tocopherol (equivalent to 25 mg of RRR-α-tocopherol) daily (37). A meta-analysis that combined the results of this study with three other RCTs associated vitamin E supplement use with a 15% lower risk of prostate cancer (35). However, two subsequent large randomized, placebo-controlled intervention trials have found either no benefit or potential harm with respect to prostate cancer risk in healthy men consuming vitamin E supplements. The Physicians’ Health Study II (PHS II) followed 14,641 healthy men, aged 50 years and older, given 400 IU of synthetic vitamin E (equivalent to 180 mg of RRR-α-tocopherol) every other day for eight years (38). Vitamin E supplementation had no effect on risk of prostate or total cancer in these middle-aged and older men. A large randomized, placebo-controlled intervention study using α-tocopherol and selenium supplementation (trial name: SELECT), alone or in combination, was recently halted because there was no evidence of benefit in preventing prostate cancer in 35,533 healthy men aged 50 years and older (39, 40). After an average of 5.5 years of follow-up in SELECT, participants taking vitamin E (400 IU/day of all-rac-α-tocopherol) alone had a higher risk of prostate cancer, but the increase was not statistically significant (41). A subsequent analysis (median follow-up of 7 years) after the trial was halted found that men who had taken the vitamin E supplement had a statistically significant, 17% higher risk of prostate cancer compared to men who took a placebo (42).

Disease Treatment

Cardiovascular disease

Observational studies have suggested that supplemental α-tocopherol might have value in the treatment of cardiovascular disease. For example, a small observational study of men who had previously undergone a coronary artery bypass surgery found those who took at least 100 IU of supplemental α-tocopherol (67 mg of RRR-α-tocopherol) daily had a reduction in the progression of coronary artery atherosclerosis measured by angiography compared to those who took less than 100 IU/day of α-tocopherol (43). A randomized, placebo-controlled intervention trial in Great Britain (the CHAOS study) found that supplementing heart disease patients with either 400 IU or 800 IU of synthetic α-tocopherol (equivalent to 180 mg or 360 mg of RRR-α-tocopherol) for an average of 18 months dramatically reduced the occurrence of nonfatal heart attacks by 77%. However, α-tocopherol supplementation did not significantly reduce total deaths from heart disease (44). Chronic renal dialysis patients are at much greater risk of dying from cardiovascular disease than the general population, and there is evidence that they are also under increased oxidative stress. Supplementation of renal dialysis patients with 800 IU of natural α-tocopherol (536 mg of RRR-α-tocopherol) for an average of 1.4 years resulted in a significantly reduced risk of heart attack compared to placebo (45). In contrast, three other intervention trials failed to find significant risk reductions with α-tocopherol supplementation. One study (ATBC), which was designed mainly to examine cancer prevention, found that 50 mg of synthetic α-tocopherol (equivalent to 25 mg of RRR-α-tocopherol) daily resulted in an 11% decrease in nonfatal heart attacks in participants who had had previous heart attacks; however, this decrease was not statistically significant (46). Similarly, two other large trials in individuals with evidence of cardiovascular disease (previous heart attack, stroke, or evidence of vascular disease) found that daily supplements of 400 IU of natural α-tocopherol (equivalent to 268 mg RRR-α-tocopherol) or 300 mg of synthetic α-tocopherol (equivalent to 150 mg of RRR-α-tocopherol) did not significantly change the risk of a subsequent heart attack or stroke (trial names: HOPE and GISSI, respectively) (47, 48). A trial in patients with either vascular disease or diabetes mellitus found that daily supplementation with 400 IU of natural α-tocopherol for an average of seven years had no effect on major cardiovascular events (myocardial infarction or stroke) or deaths; of concern, this study noted a slightly increased risk of heart failure in subjects taking vitamin E supplements (49). Thus, the majority of clinical trials using vitamin E for the treatment of heart disease have found no beneficial effects.

In an effort to inform clinical study design, an α-tocopherol dose-response study was performed in a sampling of individuals at high risk for cardiovascular events (50). Thirty-five men and women (mean age, 42 years) with hypercholesterolemia and high plasma F2-isoprostanes (i.e., enhanced systemic oxidative stress) were given either placebo or a dose of natural source α-tocopherol (RRR-α-tocopherol) of 100, 200, 400, 800, 1,600, or 3,200 IU/day for 16 weeks. Significant reductions in plasma F2-isoprostanes only occurred at 1,600 and 3,200 IU/day after 16 weeks of administration. Notably, the minimum vitamin E dose required to decrease systemic oxidative stress in this subset of high-risk individuals (1,600 IU/day) is above the tolerable upper intake level (UL) for vitamin E (1,500 IU/day; see Safety).

Diabetes mellitus

α-Tocopherol supplementation of individuals with diabetes has been proposed because diabetes appears to increase oxidative stress and because cardiovascular complications (heart attack and stroke) are among the leading causes of death in diabetics. One study found a biochemical marker of oxidative stress (urinary excretion of F2-isoprostanes) was elevated in type 2 diabetic individuals, and supplementation with 600 mg of synthetic α-tocopherol (equivalent to 300 mg of RRR-α-tocopherol) for 14 days reduced levels of the biomarker (50). Studies of the effect of α-tocopherol supplementation on blood glucose control have been contradictory. Some studies have shown that supplemental vitamin E improves insulin action and glucose disposal in type 2 diabetic (51) and non-diabetic (52, 53) individuals, while other studies have reported minimal to no improvements in glucose metabolism of type 2 diabetics (54, 55). Increased oxidative stress has also been documented in type 1 (insulin-dependent) diabetes (51). One study reported that supplementing type 1 diabetics with only 100 IU/day of synthetic α-tocopherol (equivalent to 45 mg RRR-α-tocopherol) for one month significantly improved both glycated hemoglobin and triglyceride levels (56). This study also noted nonsignificant improvements in blood glucose levels following α-tocopherol supplementation (57). Although there is reason to suspect that α-tocopherol supplementation may be beneficial in treatment for type 1 or type 2 diabetes, evidence from well-controlled clinical trials is lacking.

Dementia and Alzheimer's disease

The brain is particularly vulnerable to oxidative stress, which is thought to play a role in the pathology of neurodegenerative diseases like Alzheimer's disease (56). Additionally, some studies have documented low levels of vitamin E in cerebrospinal fluid of patients with Alzheimer's disease (58). A large placebo-controlled intervention trial in individuals with moderate neurological impairment found that supplementation with 2,000 IU of synthetic α-tocopherol daily for two years (equivalent to 900 mg/day of RRR-α-tocopherol) significantly slowed progression of Alzheimer's dementia (59). In contrast, a placebo-controlled trial in patients with mild cognitive impairment reported that the same dosage of vitamin E did not slow progression to Alzheimer's disease over a three-year period (60). After Alzheimer's disease, vascular dementia (dementia resulting from strokes) is the most common type of dementia in the US A case-control study examining risk factors for vascular dementia in elderly Japanese-American men found that supplemental vitamin E and vitamin C intake was associated with a significantly decreased risk of vascular and other types of dementia but not Alzheimer's dementia (61). Among those without dementia, vitamin E supplement use was associated with better scores on cognitive tests. Although these findings are promising, further studies are required to determine the role of α-tocopherol supplementation in the treatment of Alzheimer's disease and other types of dementia.

Cancer

Cancer cells proliferate rapidly and are resistant to death by apoptosis (programmed cell death). Cell culture studies indicate that the vitamin E ester, α-tocopheryl succinate, can inhibit proliferation and induce apoptosis in a number of cancer cell lines (62, 63). The ester form, α-tocopheryl succinate, not α-tocopherol, is required to effectively inhibit proliferation or induce cancer cell death (64). Although the mechanisms for the effects of α-tocohpheryl succinate on cancer cells are not yet clear, the fact that the ester form has no antioxidant activity argues against an antioxidant mechanism (65). Limited data from animal models of cancer indicate that α-tocopheryl succinate administered by injection may inhibit tumor growth (66-69), but much more research is required to determine whether α-tocopheryl succinate will be a useful adjunct to cancer therapy in humans. Certainly, administration by injection would be necessary for any benefit, because α-tocopheryl succinate taken orally is cleaved to form α-tocopherol in the intestine (70). There is currently no evidence in humans that taking oral α-tocopheryl succinate supplements delivers α-tocopheryl succinate to tissues.

Sources

Food sources

Major sources of α-tocopherol in the American diet include vegetable oils (olive, sunflower, and safflower oils), nuts, whole grains, and green leafy vegetables (Table 2). All eight forms of vitamin E (α-, β-, γ-, and δ-tocopherols and tocotrienols) occur naturally in foods but in varying amounts. For more information on the nutrient content of foods, search the USDA food composition database.

Table 2. Some Food Sources of Vitamin E
Food Serving α-Tocopherol (mg) γ-Tocopherol (mg)
Olive oil 1 tablespoon 1.9 0.1
Soybean oil 1 tablespoon 1.1 8.7
Corn oil 1 tablespoon 1.9 8.2
Canola oil 1 tablespoon 2.4 3.8
Safflower oil 1 tablespoon 4.6 0.1
Sunflower oil 1 tablespoon 5.6 0.7
Almonds 1 ounce 7.4 0.2
Hazelnuts 1 ounce 4.3 0
Peanuts 1 ounce 2.4 2.4
Spinach ½ cup, raw 0.3 0
Carrots ½ cup, raw chopped 0.4 0
Avocado (California) 1 fruit 2.7 0.4

Supplements

α-Tocopherol

In the US, the average intake of α-tocopherol from food (including enriched and fortified sources) for individuals 2 years and older is 6.9 mg/day (14); this level is well below the RDA of 15 mg/day of RRR-α-tocopherol (4). Many scientists believe it is difficult for an individual to consume more than 15 mg/day of α-tocopherol from food alone without increasing fat intake above recommended levels. All α-tocopherol in food is the form of the isomer RRR-α-tocopherol. The same is not always true for supplements. Vitamin E supplements generally contain 100 IU to 1,000 IU of α-tocopherol. Supplements made from entirely natural sources contain only RRR-α-tocopherol (also labeled d-α-tocopherol). RRR-α-tocopherol is the isomer preferred for use by the body, making it the most bioavailable form of α-tocopherol. Synthetic α-tocopherol, which is often found in fortified foods and nutritional supplements, is usually labeled all-rac-α-tocopherol or dl-α-tocopherol, meaning that all eight isomers of α-tocopherol are present in the mixture. Because half of the isomers of α-tocopherol present in all-rac-α-tocopherol are not usable by the body, synthetic α-tocopherol is less bioavailable and only half as potent. To calculate the number of mg of bioavailable α-tocopherol present in a supplement, use the following formulas:

  • RRR-α-tocopherol (natural or d-α-tocopherol):
    IU x 0.67 = mg RRR-α-tocopherol.
    Example: 100 IU = 67 mg
    (100 IU of natural vitamin E provides 67 mg of RRR-α-tocopherol)
  • all-rac-α-tocopherol (synthetic or dl-α-tocopherol):
    IU x 0.45 = mg RRR-α-tocopherol.
    Example: 100 IU = 45 mg
    (100 IU of synthetic vitamin E provides 45 mg of RRR-α-tocopherol)
α-Tocopheryl succinate and α-tocopheryl acetate (α-tocopheryl esters)

α-Tocopherol supplements are available in the ester forms: α-tocopheryl succinate and α-tocopheryl acetate. Tocopherol esters are more resistant to oxidation during storage than unesterified tocopherols. When taken orally, the succinate or acetate moiety is removed from α-tocopherol in the intestine. The bioavailability of α-tocopherol from α-tocopheryl succinate and α-tocopheryl acetate is equivalent to that of free α-tocopherol. Because international units (IU) for α-tocopherol esters are adjusted for molecular weight, the conversion factors for determining the amount of bioavailable α-tocopherol provided by α-tocopheryl succinate and α-tocopheryl acetate are not different from those used for α-tocopherol (see formulas) (4). The ester α-tocopheryl succinate, not α-tocopherol, is required to effectively inhibit growth and induce death in cancer cells grown in culture (see Disease Treatment: Cancer). However, there is currently no evidence in humans that taking oral α-tocopheryl succinate supplements delivers α-tocopheryl succinate to tissues.

α-Tocopheryl phosphates (Ester-E®)

There is currently no published evidence that supplements containing α-tocopheryl phosphates are more efficiently absorbed or have greater bioavailability in humans than supplements containing α-tocopherol.

γ-Tocopherol

γ-Tocopherol supplements and mixed tocopherol supplements are also commercially available (71). The amounts of α- and γ-tocopherol in mixed tocopherol supplements vary, so it is important to read the label to determine the amount of each tocopherol present in supplements.

Safety

Toxicity

Few side effects have been noted in adults taking supplements of less than 2,000 mg of α-tocopherol daily (RRR- or all-rac-α-tocopherol). However, most studies of toxicity or side effects of α-tocopherol supplementation have lasted only a few weeks to a few months, and side effects occurring as a result of long-term α-tocopherol supplementation have not been adequately studied. The most worrisome possibility is that of impaired blood clotting, which may increase the likelihood of hemorrhage in some individuals. The Food and Nutrition Board of the Institute of Medicine established a tolerable upper intake level (UL) for α-tocopherol supplements based on the prevention of hemorrhage (Table 3). The Board felt that 1,000 mg/day of α-tocopherol in any form (equivalent to 1,500 IU/day of RRR-α-tocopherol or 1,100 IU/day of all-rac-α-tocopherol) would be the highest dose unlikely to result in hemorrhage in almost all adults (4). Although only certain isomers of α-tocopherol are retained in the circulation, all forms are absorbed and metabolized by the liver. The rationale that any form of α-tocopherol (natural or synthetic) can be absorbed and thus could be potentially harmful is the basis for a UL that refers to all forms of α-tocopherol.

Some physicians recommend discontinuing high-dose vitamin E supplementation one month before elective surgery to decrease the risk of hemorrhage. Premature infants appear to be especially vulnerable to adverse effects of α-tocopherol supplementation, which should be used only under controlled supervision by a pediatrician (71). Supplementation with 400 IU/day of vitamin E has been found to accelerate the progression of retinitis pigmentosa that is not associated with vitamin E deficiency (72).

Table 3. Tolerable Upper Intake Level (UL) for α-Tocopherol
Age Group mg/day IU/day d-α-Tocopherol
Infants 0-12 months  Not Possible to Establish*
Children 1-3 years 200 300
Children 4-8 years 300 450
Children 9-13 years 600 900
Adolescents 14-18 years 800 1,200
Adults 19 years and older 1,000 1,500
*Source of intake should be from food and formula only.
Vitamin E supplementation and all-cause mortality

meta-analysis that combined the results of 19 clinical trials of vitamin E supplementation for various diseases, including heart disease, end-stage renal failure, and Alzheimer's disease, reported that adults who took supplements of 400 IU/day or more were 6% more likely to die from any cause than those who did not take vitamin E supplements (73). However, further breakdown of the risk by vitamin E dose and adjustment for other vitamin and mineral supplements revealed that the increased risk of death was statistically significant only at a dose of 2,000 IU/day, which is higher than the UL for adults. Additionally, three other meta-analyses that combined the results of randomized controlled trials designed to evaluate the efficacy of vitamin E supplementation for the prevention or treatment of cardiovascular disease found no evidence that vitamin E supplementation up to 800 IU/day significantly increased or decreased cardiovascular disease mortality or all-cause mortality (74-76). Additionally, a more recent meta-analysis of 57 randomized controlled trials found that vitamin E supplementation, up to doses of 5,500 IU/day, had no effect on all-cause mortality (77). Furthermore, a meta-analysis of 68 randomized trials found that supplemental vitamin E, singly or in combination with other antioxidant supplements, did not significantly alter risk of all-cause mortality (78). At present, there is no convincing evidence that vitamin E supplementation up to 800 IU/day increases the risk of death from cardiovascular disease or other causes.

Drug interactions

Use of vitamin E supplements may increase the risk of bleeding in individuals taking anticoagulant drugs, such as warfarin (Coumadin); antiplatelet drugs, such as clopidogrel (Plavix) and dipyridamole (Persantine); and non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, and others. Also, individuals on anticoagulant therapy (blood thinners) or individuals who are vitamin K deficient should not take α-tocopherol supplements without close medical supervision because of the increased risk of hemorrhage (4). A number of medications may decrease the absorption of vitamin E, including cholestyramine, colestipol, isoniazid, mineral oil, orlistat, sucralfate, and the fat substitute, olestra. Anticonvulsant drugs, such as phenobarbital, phenytoin, or carbamazepine, may decrease plasma levels of vitamin E (4, 71).

Antioxidants and HMG-CoA reductase inhibitors (statins)

A three-year randomized controlled trial in 160 patients with documented coronary heart disease (CHD) and low HDL levels found that a combination of simvastatin (Zocor) and niacin increased HDL2 levels, inhibited the progression of coronary artery stenosis (narrowing), and decreased the frequency of cardiovascular events, such as myocardial infarction and stroke (79). Surprisingly, when an antioxidant combination (1,000 mg of vitamin C, 800 IU of α-tocopherol, 100 mcg of selenium, and 25 mg of β-carotene daily) was taken with the simvastatin-niacin combination, the protective effects were diminished. However, in a much larger randomized controlled trial of simvastatin and an antioxidant combination (600 mg of vitamin E, 250 mg of vitamin C, and 20 mg of β-carotene daily) in more than 20,000 men and women with coronary artery disease or diabetes, the antioxidant combination did not adversely affect the cardioprotective effects of simvastatin therapy over a five-year period (80). These contradictory findings indicate that further research is needed on potential interactions between antioxidant supplementation and cholesterol-lowering agents like HMG-CoA reductase inhibitors (statins).

Linus Pauling Institute Recommendation

The Recommended Dietary Allowance (RDA) for vitamin E for adult men and women is 15 mg (22.5 IU) per day. Notably, more than 90% of individuals 2 years of age and older in the US do not meet the daily requirement for vitamin E from food sources alone, but there is inconclusive evidence that high-dose supplemental vitamin E reduces chronic disease risk. Therefore, LPI recommends that generally healthy adults (aged 19 years and older) take a daily multivitamin/mineral supplement, which usually contains 30 IU of synthetic vitamin E, or 90% of the RDA. There is no conclusive evidence that supplementation with high-dose vitamin E lowers chronic disease risk, and a few studies have reported harmful effects in some subpopulations.

Older adults (>50 years)

The Linus Pauling Institute’s recommendation to take a daily multivitamin/mineral (MVM) supplement containing vitamin E is also appropriate for generally healthy older adults. MVMs typically contain 30 IU of synthetic vitamin E, or 90% of the RDA.


Authors and Reviewers

Originally written in 2000 by: 
Jane Higdon, Ph.D. 
Linus Pauling Institute
Oregon State University

Updated in November 2004 by: 
Jane Higdon, Ph.D. 
Linus Pauling Institute 
Oregon State University

Updated in June 2008 by: 
Victoria J. Drake, Ph.D. 
Linus Pauling Institute 
Oregon State University

Reviewed in June 2008 by: 
Maret G. Traber, Ph.D. 
Professor of Nutrition and Exercise Sciences 
Principal Investigator, Linus Pauling Institute 
Oregon State University

Last updated 11/17/11  Copyright 2000-2015  Linus Pauling Institute


References

1.  Traber MG. Utilization of vitamin E. Biofactors. 1999;10(2-3):115-120.  (PubMed)

2.  Traber MG. Vitamin E. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease. Philadelphia: Lippincott Williams & Wilkiins; 2006:396-411.

3.  Bruno RS, Leonard SW, Atkinson J, et al. Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med. 2006;40(4):689-697.  (PubMed)

4.  Food and Nutrition Board, Institute of Medicine. Vitamin E. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington D.C.: National Academy Press; 2000:186-283.  (National Academy Press)

5.  Traber MG. Does vitamin E decrease heart attack risk? summary and implications with respect to dietary recommendations. J Nutr. 2001;131(2):395S-397S.  (PubMed)

6.  Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr. 2007;27:347-362.  (PubMed)

7.  Traber MG, Elsner A, Brigelius-Flohe R. Synthetic as compared with natural vitamin E is preferentially excreted as α-CEHC in human urine: studies using deuterated α-tocopheryl acetates. FEBS Lett. 1998;437(1-2):145-148.  (PubMed)

8.  Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. γ-Tocopherol traps mutagenic electrophiles such as NO(X) and complements α-tocopherol: physiological implications. Proc Natl Acad Sci U S A. 1997;94(7):3217-3222.  (PubMed)

9.  Li D, Saldeen T, Mehta JL. γ-Tocopherol decreases ox-LDL-mediated activation of nuclear factor-kappaB and apoptosis in human coronary artery endothelial cells. Biochem Biophys Res Commun. 1999;259(1):157-161.  (PubMed)

10.  Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92(24):2018-2023.  (PubMed)

11.  Jiang Q, Christen S, Shigenaga MK, Ames BN. Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr. 2001;74(6):714-722.  (PubMed)

12.  Traber MG. Vitamin E. In: Bowman BA, Russell RM, eds. Present Knowledge in Nutrition. 9th ed. Volume 1. Washington, D.C.: ILSI Press; 2006:211-219.

13.  Ford ES, Sowell A. Serum α-tocopherol status in the United States population: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 1999;150(3):290-300.  (PubMed)

14.  Fulgoni VL 3rd, Keast DR, Bailey, Dwyer J. Foods, fortificants, and supplements: where do Americans get their nutrients? J Nutr. 2011;141(10):18-47-1854.  (PubMed)

15.  Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139(12):1180-1189.  (PubMed)

16.  Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334(18):1156-1162.  (PubMed)

17.  Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328(20):1450-1456.  (PubMed)

18.  Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328(20):1444-1449.  (PubMed)

19.  Cherubini A, Zuliani G, Costantini F, et al. High vitamin E plasma levels and low low-density lipoprotein oxidation are associated with the absence of atherosclerosis in octogenarians. J Am Geriatr Soc. 2001;49(5):651-654.  (PubMed)

20.  Gale CR, Ashurst HE, Powers HJ, Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr. 2001;74(3):402-408.  (PubMed)

21.  McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL. Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). J Am Coll Cardiol. 2001;38(7):1788-1794.  (PubMed)

22.  Simon E, Gariepy J, Cogny A, Moatti N, Simon A, Paul JL. Erythrocyte, but not plasma, vitamin E concentration is associated with carotid intima-media thickening in asymptomatic men at risk for cardiovascular disease. Atherosclerosis. 2001;159(1):193-200.  (PubMed)

23.  Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65.  (PubMed)

24.  Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007;116(13):1497-1503.  (PubMed)

25.  Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008;300(18):2123-2133.  (PubMed)

26.  Traber MG, Frei B, Beckman JS. Vitamin E revisited: do new data validate benefits for chronic disease prevention? Curr Opin Lipidol. 2008;19(1):30-38.  (PubMed)

27.  West AL, Oren GA, Moroi SE. Evidence for the use of nutritional supplements and herbal medicines in common eye diseases. Am J Ophthalmol. 2006;141(1):157-166.  (PubMed)

28.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and β carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119(10):1439-1452.  (PubMed)

29.  Gritz DC, Srinivasan M, Smith SD, et al. The Antioxidants in Prevention of Cataracts Study: effects of antioxidant supplements on cataract progression in South India. Br J Ophthalmol. 2006;90(7):847-851.  (PubMed)

30.  McNeil JJ, Robman L, Tikellis G, Sinclair MI, McCarty CA, Taylor HR. Vitamin E supplementation and cataract: randomized controlled trial. Ophthalmology. 2004;111(1):75-84.  (PubMed)

31.  Teikari JM, Rautalahti M, Haukka J, et al. Incidence of cataract operations in Finnish male smokers unaffected by α tocopherol or β carotene supplements. J Epidemiol Community Health. 1998;52(7):468-472.  (PubMed)

32.  Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA. 1997;277(17):1380-1386.  (PubMed)

33.  Han SN, Meydani SN. Vitamin E and infectious diseases in the aged. Proc Nutr Soc. 1999;58(3):697-705.  (PubMed)

34.  Meydani SN, Leka LS, Fine BC, et al. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA. 2004;292(7):828-836.  (PubMed)

35.  Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med. 2008;177(5):524-530.  (PubMed)

36.  Alkhenizan A, Hafez K. The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. Ann Saudi Med. 2007;27(6):409-414.  (PubMed)

37.  Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90(6):440-446.  (PubMed)

38.  Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009;301(1):52-62.  (PubMed)

39.  Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol. 2001;166(4):1311-1315.  (PubMed)

40.  National Cancer Institute. Review of Prostate Cancer Prevention Study Shows No Benefit for Use of Selenium and Vitamin E Supplements. [Web page]. http://www.cancer.gov/newscenter/pressreleases/SELECTresults2008. Accessed 10/28/08.

41.  Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51.   (PubMed)

42.  Klein EA, Thompson IM, Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 306(14):1549-1556.  (PubMed)

43.  Azen SP, Qian D, Mack WJ, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 1996;94(10):2369-2372.  (PubMed)

44.  Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347(9004):781-786.  (PubMed)

45.  Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356(9237):1213-1218.  (PubMed)

46.  Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349(9067):1715-1720.  (PubMed)

47.  Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):154-160.  (PubMed)

48.  Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-455.  (PubMed)

49.  Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338-1347.  (PubMed)

50.  Roberts LJ 2nd, Oats JA, Linton MF, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med. 2007;43(10):1388-1393.  (PubMed)

51.  Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99(2):224-229.  (PubMed)

52.  Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr. 1993;57(5):650-656.  (PubMed)

53.  Paolisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr. 1994;59(6):1291-1296.  (PubMed)

54.  Paolisso G, D'Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care. 1993;16(11):1433-1437.  (PubMed)

55.  Reaven PD, Herold DA, Barnett J, Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 1995;18(6):807-816.  (PubMed)

56.  Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr. 1996;15(5):458-461.  (PubMed)

57.  Meydani M. Antioxidants and cognitive function. Nutr Rev. 2001;59(8 Pt 2):S75-80; discussion S80-72.

58.  Kontush K, Schekatolina S. Vitamin E in neurodegenerative disorders: Alzheimer's disease. Ann N Y Acad Sci. 2004;1031:249-262.  (PubMed)

59.  Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336(17):1216-1222.  (PubMed)

60.  Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.  (PubMed)

61.  Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000;54(6):1265-1272.  (PubMed)

62.  Yu W, Sanders BG, Kline K. RRR-α-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res. 2003;63(10):2483-2491.  (PubMed)

63.  You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline K. Role of extracellular signal-regulated kinase pathway in RRR-α-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002;33(4):228-236.  (PubMed)

64.  Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 2001;15(2):403-415.  (PubMed)

65.  Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002;76(4):703-716.  (PubMed)

66.  Weber T, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res. 2002;8(3):863-869.  (PubMed)

67.  Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery. 2002;131(1):85-91.  (PubMed)

68.  Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res. 2000;93(1):163-170.  (PubMed)

69.  Quin J, Engle D, Litwiller A, et al. Vitamin E succinate decreases lung cancer tumor growth in mice. J Surg Res. 2005;127(2):139-143.  (PubMed)

70.  Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G. Biokinetics in humans of RRR-α-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E. Free Radic Biol Med. 1995;19(5):591-598.  (PubMed)

71.  Hendler SS, Rorvik DR, eds. PDR for Nutritional Supplements. Montvale: Medical Economics Company, Inc; 2001.

72.  Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111(6):761-772.   (PubMed)

73.  Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.  (PubMed)

74.  Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004;19(4):380-389.  (PubMed)

75.  Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164(14):1552-1556.  (PubMed)

76.   Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011; 4(2):158-170  (PubMed) 

77.  Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361(9374):2017-2023.  (PubMed)

78.  Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-857.  (PubMed)

79.  Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.  (PubMed)

80.  Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract. 2002;56(1):53-56.  (PubMed)